The newly-appointed chief financial officer at Array BioPharma Inc. in Boulder will step down after three months on the job.
Patricia Henahan, who served as the financial chiefs of Hospira and AstraZeneca and in executive roles with Eli Lilly and MedImmune, plans to resign from her position on Dec. 17, Array officials with the U.S. Securities and Exchange Commission. She was on Sept. 8.
David Horin, who served as Array’s interim CFO prior to Henahan’s appointment, again will fill that role.
Array officials could not be immediately reached for comment.
Array recently landed a new development partner for its pair of late-stage cancer drugs. The Boulder biotech company to develop and commercialize binimetinib and encorafenib, which are protein inhibitors for melanoma and ovarian cancer, respectively.
Previous partner Novartis had to divest its assets related to BRAF and MEK inhibitor drugs as part of its acquisition of GlaxoSmithKline.
Alicia Wallace: 303-954-1939, awallace@denverpost.com or @aliciawallace
